A
Angela Dispenzieri
Researcher at Mayo Clinic
Publications - 1212
Citations - 72269
Angela Dispenzieri is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Multiple myeloma & Amyloidosis. The author has an hindex of 117, co-authored 1107 publications receiving 60367 citations. Previous affiliations of Angela Dispenzieri include University of Rochester & Kyungpook National University Hospital.
Papers
More filters
Journal ArticleDOI
Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement.
TL;DR: Two new drugs have been developed that treat systemic amyloidosis by inhibiting the progression of misfolding, aggregation, and deposition of protein in the form of insoluble material termed amyloids by the immune system.
Journal ArticleDOI
Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis
Surbhi Sidana,Nidhi Tandon,Morie A. Gertz,Angela Dispenzieri,Francis K. Buadi,Martha Q. Lacy,David Dingli,Amie Fonder,Suzanne R. Hayman,Miriam Hobbs,Wilson I. Gonsalves,Yi Lisa Hwa,Prashant Kapoor,Robert A. Kyle,Nelson Leung,Ronald S. Go,John A. Lust,Stephen J. Russell,Steven R. Zeldenrust,S. Vincent Rajkumar,William J. Hogan,Shaji Kumar +21 more
TL;DR: Impact ofmelphalan was dose-dependent, with cumulative melphalan exposure of >150 mg (median: three cycles) resulting in lower yields, therefore, duration of melPHalan exposure prior to stem cell collection should be limited, ideally, not exceeding more than two cycles of treatment.
Journal ArticleDOI
Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.
Marcella Tschautscher,S. Vincent Rajkumar,Francis K. Buadi,Morie A. Gertz,Martha Q. Lacy,Angela Dispenzieri,Suzanne R. Hayman,Yi Lisa Hwa,Amie Fonder,Miriam Hobbs,Steven R. Zeldenrust,John A. Lust,Nelson Leung,Prashant Kapoor,Taxiarchis Kourelis,Rahma Warsame,Ronald S. Go,Wilson I. Gonsalves,Robert A. Kyle,Shaji Kumar +19 more
TL;DR: Achievement of a complete response to therapy has been associated with improved outcomes in patients with multiple myeloma and increasing application of minima has been linked to improved outcomes.
Journal ArticleDOI
Clinical activity of systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.
Joselle Cook,Kah Whye Peng,Susan Geyer,Brenda Ginos,Amylou C. Dueck,Nandakumar Packiriswamy,Lianwen Zhang,Beth Brunton,Baskar Balakrishnan,Thomas E. Witzig,Stephen M. Broski,Mrinal M. Patnaik,Francis K. Buadi,Angela Dispenzieri,Morie A. Gertz,Leif Bergsagel,S. Vincent Rajkumar,Shaji Kumar,Stephen J. Russell,Martha Q. Lacy +19 more
TL;DR: VSV-IFNβ-NIS can be safely administered by IV infusion among heavily pretreated pts with hematologic malignancies and appears to be most effective at DL4 among patients with TCL, with an ongoing CR in a patient atDL4 more than 1 year post administration.
Journal ArticleDOI
Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis
TL;DR: The question regarding the added value of incorporating bortezomib into first-line therapy among patients with AL amyloidosis is still not adequately answered, so the results of a randomized clinical trial are continued to await.